UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057538
Receipt number R000065735
Scientific Title Examination of the effect of food containing lactic acid bacteria Lactobaciilus salivarius WB21 on oral Candida species
Date of disclosure of the study information 2025/06/01
Last modified on 2025/09/30 17:38:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of the effect of food containing lactic acid bacteria WB21 on oral Candida species

Acronym

Effect of tablets containing lactic acid bacteria WB21 on oral Candida

Scientific Title

Examination of the effect of food containing lactic acid bacteria Lactobaciilus salivarius WB21 on oral Candida species

Scientific Title:Acronym

Effect of tablets containing Lactobacillus salivarius WB21 in oral Candida species

Region

Japan


Condition

Condition

oral candidiasis

Classification by specialty

Dental medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prevent oral candidiasis, we aimed to clarify whether continuous intake of food containing the lactic acid bacterium Lactobacillus salivarius WB21 (WB21), which has been shown to inhibit the growth of Candida albicans in in vitro studies, inhibits the growth of Candida in the oral cavity of elderly people who have Candida in their oral cavity, and thus inhibits the onset of oral candidiasis.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the number of Candida species in the mouth

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Study participants were asked to take "Avantbise Oral Tablets" (Wakamoto Pharmaceutical Co., Ltd.), a food containing Lactobacillus salivarius WB21, three times a day for two consecutive weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Residents of a certain nursing home in Fukuoka who have been found to have the presence of Candida in their mouths

Key exclusion criteria

Those who are already using food containing WB21 / Those taking antibiotics / Those with a history of milk allergy or food allergy to food ingredients / Those who the researcher judges to be inappropriate as study participants

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Nao
Middle name
Last name Taniguchi

Organization

Fukuoka Dental College

Division name

Department of Preventive and Public Health Dentistry

Zip code

8140175

Address

2-15-1 Tamura, Sawara-ku, Fukuoka, Japan

TEL

81-92-801-0616

Email

naojsz@fdcnet.ac.jp


Public contact

Name of contact person

1st name Nao
Middle name
Last name Taniguchi

Organization

Fukuoka Dental College

Division name

Department of Preventive and Public Health Dentistry

Zip code

8140175

Address

2-15-1, Tamura, Sawara-ku, Fukuoka, Japan

TEL

81-92-801-0616

Homepage URL


Email

naojsz@fdcnet.ac.jp


Sponsor or person

Institute

Fukuoka Dental College

Institute

Department

Personal name



Funding Source

Organization

Fukuoka Dental College

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Fukuoka Gakuen Ethics Committee

Address

2-15-1, Tamura, Sawara-ku, Fukuoka, Japan

Tel

81-91-801-0425

Email

shomu@fdcnet.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 04 Month 07 Day

Date of IRB


Anticipated trial start date

2025 Year 05 Month 01 Day

Last follow-up date

2025 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 04 Month 07 Day

Last modified on

2025 Year 09 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065735